Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients
Status:
Completed
Trial end date:
2017-06-16
Target enrollment:
Participant gender:
Summary
This study will evaluate whether a test for Cytomegalovirus (CMV) specific cell-mediated
immunity can be used to determine whether patients who complete a course of therapy for CMV
viremia need secondary antiviral prophylaxis. Subjects that have negative CMV CMI will
receive antiviral prophylaxis for 2 months and those with positive CMV CMI will have their
prophylaxis stopped.